Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $14.00 price objective on the stock. Chardan Capital’s target price would indicate a potential upside of 191.67% from the stock’s previous close.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Finally, Roth Capital started coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Coya Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $15.33.

Coya Therapeutics Trading Up 3.4%

Shares of NASDAQ COYA opened at $4.80 on Wednesday. The business has a fifty day simple moving average of $4.86 and a 200 day simple moving average of $4.67. The firm has a market capitalization of $112.61 million, a price-to-earnings ratio of -4.17 and a beta of 0.60. Coya Therapeutics has a one year low of $3.71 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. On average, research analysts anticipate that Coya Therapeutics will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new position in Coya Therapeutics in the fourth quarter valued at about $47,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics during the fourth quarter worth about $66,000. Oppenheimer & Co. Inc. bought a new position in Coya Therapeutics during the fourth quarter worth about $81,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Coya Therapeutics during the second quarter worth about $119,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.